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Abstract 
Despite decades of research on necrotizing enterocolitis (NEC), the outlook for infants 
afflicted by this devastating disease is all too often bleak.  The aim of this symposium at 
the BAPS conference in Amsterdam was to highlight recent advances in the knowledge 
of the epidemiology and diagnosis of NEC. There were important contributions on the 
disease in the United Kingdom, both from a neonatal and a surgical point of view, 
whereas colleagues from the Netherlands and elsewhere in Europe shared their insights 
into novel diagnostic tools, both biofluid and imaging based. 
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Necrotizing enterocolitis needs no introduction to the paediatric surgeon. The 
presentation of a sick premature neonate who has been tolerating enteral feeds but has 
developed abdominal distension, increased aspirates and has pneumatosis intestinalis and 
pneumoperitoneum is all too familiar, as are the findings at laparotomy – necrotic bowel 
requiring extensive resection, and the outcomes – mortality, neurodevelopmental 
impairment and short bowel syndrome [1]. Probiotics have not eradicated the disease [2] 
and the surgical outcomes do not appear to have improved over twenty years [3, 4], so 
research into the epidemiology and rapid diagnosis of the disease is urgently required. 
Although animal models have been used and novel therapies suggested in these models, 
careful clinical research continues to deliver important data which can hopefully help 
paediatric surgeons to improve outcomes. The aim of the Symposium at the BAPS 
Congress in Amsterdam was to provide the paediatric surgeons faced with this disease 
up-to date information about the epidemiology of NEC across the UK, and novel data on 
biomarkers and physiological measurements that colleagues in Europe are using to shed 
light on how intervention might be made in a more timely manner in the future. 
Epidemiology 
Although comprehensive data on NEC incidence and/or surgical outcomes is available 
from some counties, areas, or healthcare systems, including population-based data from 
Sweden [5] and the Vermont-Oxford Network Hull VON [6], data from the UK has been 
lacking, except for a survey study of 158 NICUs [7]. The UK National Confidential 
Enquiry into Patient Outcome and Death report on paediatric surgery in 2011 highlighted 
the gaps in our knowledge about incidence, epidemiology and outcomes of NEC in the 
UK [8], and following this two national prospective studies were initiated to fill some of 
these gaps. The UK Neonatal NEC Study, slightly misleadingly, covered England only, 
but prospectively acquired data from all from all 163 neonatal units between December 
2011 and September 2014 and will provide an important neonatal perspective on risk 
factors and antecedent feeding practices. Professor Neena Modi, from Imperial College 
London, gave a sneak preview into these as yet unpublished data, including the 
development of a consistent case-definition tool for surveillance, and we look forward to 
the publication of these important data. The other UK study presented at the meeting, the 
British Association of Paediatric Surgeons Congenital Anomalies Surveillance System 
 4 
(BAPS-CASS) Surgical NEC study, did indeed cover the whole of the UK and Ireland by 
collecting data from 28 neonatal surgical centres over one year. This study complements 
the neonatal study by providing data on surgical management and outcomes of those 
infants that required surgery. Miss Kokila Lakhoo presented the data from this study on 
behalf of BAPS-CASS, which showed that 236 infants required surgery in the UK over 
one year, and highlighted the variation in surgical practices. In part, this variation is due 
to the heterogeneity of disease in terms of presentation and area of intestine affected, but 
also is a result of the lack of evidence for the optimal surgical management. |We also 
eagerly look forward to publication of the BAPS-CASS study. In both epidemiological 
studies, infants were identified who died without having surgery. In addition, there are 
those infants who have a laparotomy in which the whole intestine is necrotic prompting a 
decision to withdraw active care. This then leads to the question of whether paediatric 
surgeons should be intervening earlier, and if so, what should be the indications for 
surgery? This area of clinical research, pursued actively by our Dutch colleagues, formed 
the second part of the NEC symposium. 
Early diagnosis 
Abdominal x-ray has long been the mainstay of diagnosis of definite NEC (pneumatosis 
intestinalis) and provides the only universally accepted indication for operation 
(pneumoperitoneum). Blood work in current routine practice is limited to non-specific 
markers of systemic disease (C-reactive protein, platelets, white-blood cells) that are 
more indicative to neonatal intensivists to guide medical than useful as an indication to 
paediatric surgeons on when to operate. Ernst Van Heurn, based in Amsterdam in 
collaboration with Joep Derikx, presented data on intestinal fatty acid binding protein (I-
FABP, measured in urine), calprotectin (measured in faeces) and serum amyloid A (SAA, 
measured in urine) in early diagnosis of NEC and attempted to answer the questions: (i) 
can these markers be used for early diagnosis?; (ii) can they predict severity of disease?; 
and (iii) can they be used to guide the re-introduction of enteral feeds? Ernst showed us 
that the combination of I-FABP and calprotectin gave the highest accuracy in the 
diagnosis of NEC [9], that SAA together with platelets were the most predictive of 
surgical NEC [10] and that I-FABP can be useful to direct re-feeding following surgery 
[11]. However, use of these markers is only useful if the turnaround time by hospital 
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laboratories is fast enough for them to be used in clinical decision making and it remains 
to be seen whether these markers will enter widespread clinical practice. Circulating 
cytokines are markers of systemic immune status, and pro-inflammatory cytokines have 
long been known to be elevated in NEC. There has been limited information, however, 
on whether cytokine measurements can be useful in diagnosis or risk assessment in NEC 
[12], and this was the topic of the presentation by Thomas Benkoe, from Vienna. Using a 
cytokine array to measure pro-inflammatory (IL-1b, IL-2,IL-5,IL-6, IL-8, IL-12, IFN-
gamma, TNF-alpha, TNF-beta) and anti-inflammatory cytokines (IL-4, IL-10), only IL-
10,IL-8 and IL-6 were shown to be significantly higher in surgical NEC than in matched 
controls [13], similar findings on IL-6 and IL-8 being reported by others [14] [15]. 
Thomas then focussed in on IL-8, which is a chemoattractant for neutrophils and 
macrophages whose intestinal expression has been linked with NEC [16], and showed 
that IL-8 is a suitable marker for preoperative risk assessment, that IL-8 levels obtained 
within 6 hours prior to surgery correlate with the actual intraoperative disease extent [17] 
and that high levels correlate with 60-day mortality [18]. Interestingly, although IL-8 is in 
theory non-specific, whereas I-FABP discussed above is specific for the gut, IL-8 may in 
fact be a better marker than I-FABP [19]. In Thomas’ hospital, and potentially many 
others, IL-8 is available as a routine test, so unlike many laboratory-based biomarkers, 
might prove to be clinically useful, although precise cutoffs and criteria for intervention 
must be developed. Of course, imaging methodologies have the potential advantage of 
either real-time information, or at least a faster reporting time than measurement of  
biomarkers in body fluids, at least until one of these biomarkers is adopted for a point-of-
care test. Jan Hulscher, from Groningen, has been exploring the use of near infra-red 
spectroscopy (NIRS) in NEC, and shared his data in his symposium talk. NIRS provides 
a non-invasive measurement of tissue oxygen saturation, which potentially allows a real-
time window into intestinal perfusion, which is measured as tissue fractional oxygen 
saturation after taking into account arterial saturation concomitantly measured by pulse 
oximetry. Although one might assume that in NEC infants, intestinal perfusion would be 
lower in infants predisposed to NEC, in fact Jan showed that cerebral oxygenation, rather 
than intestinal oxygenation, is impaired in the first days of life in infants that go on to get 
NEC, whereas intestinal perfusion is impaired immediately preceding clinical NEC [20]. 
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In a further study, although NIRS could not distinguish between definite NEC and 
absence of NEC, it could differentiate between complicated from uncomplicated NEC 
[21]. Encouragingly, these differences in NIRS readings also correlated well with I-
FABP levels, thus validating the use of NIRS to examine intestinal impairment [22]. 
However, Jan stressed that at the present time, because of the high variability, NIRS was 
currently useful to examine the pathogenesis of NEC at a group level, but that it was not 
currently ready for prime-time on an individual patient basis, in other words the holy 
grail of indicating which infants require urgent surgical intervention. 
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